Latest Insider Transactions at Pulse Biosciences, Inc. (PLSE)
This section provides a real-time view of insider transactions for Pulse Biosciences, Inc. (PLSE). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Pulse Biosciences, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Pulse Biosciences, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 09
2023
|
Robert W Duggan |
BUY
Open market or private purchase
|
Direct |
10,022,937
+24.79%
|
$60,137,622
$6.51 P/Share
|
|
Oct 07
2022
|
Mitchell E. Levinson Chief Strategy Officer |
BUY
Open market or private purchase
|
Indirect |
22,010
+44.74%
|
$44,020
$2.26 P/Share
|
|
Oct 07
2022
|
Mitchell E. Levinson Chief Strategy Officer |
BUY
Open market or private purchase
|
Direct |
8,770
+15.93%
|
$17,540
$2.29 P/Share
|
|
Sep 30
2022
|
Kevin Patrick Danahy Chief Commercial Officer |
BUY
Open market or private purchase
|
Direct |
6,500
+50.0%
|
$13,000
$2.3 P/Share
|
|
Jun 09
2022
|
Darrin Uecker Chief Technology Officer |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
7,365
+5.09%
|
-
|
|
Jun 09
2022
|
Mitchell E. Levinson Chief Strategy Officer |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
1,243
+16.34%
|
-
|
|
Jun 09
2022
|
Mitchell E. Levinson Chief Strategy Officer |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
10,935
+22.57%
|
-
|
|
Jun 09
2022
|
Maky Zanganeh Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
86,668
+16.39%
|
-
|
|
Jun 09
2022
|
Robert W Duggan |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
81,025
+16.47%
|
-
|
|
Jun 09
2022
|
Robert W Duggan |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
5,683,163
+21.8%
|
-
|
|
Jun 30
2021
|
Robert W Duggan |
BUY
Open market or private purchase
|
Direct |
3,048,780
+17.17%
|
$48,780,480
$16.4 P/Share
|
|
Jun 01
2021
|
Ed Ebbers EVP & GM, Dermatology |
SELL
Payment of exercise price or tax liability
|
Direct |
1,485
-3.64%
|
$26,730
$18.76 P/Share
|
|
Jan 25
2021
|
Darrin Uecker Chief Technology Officer |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
1,284
+0.99%
|
$8,988
$7.01 P/Share
|
|
Jan 20
2021
|
Mitchell E. Levinson Chief Strategy Officer |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
164
+3.12%
|
$1,148
$7.01 P/Share
|
|
Jan 19
2021
|
Maky Zanganeh Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
307
+0.29%
|
$2,149
$7.01 P/Share
|
|
Jan 08
2021
|
Maky Zanganeh Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
3,000
+0.84%
|
$21,000
$7.01 P/Share
|
|
Dec 29
2020
|
Robert W Duggan |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
8,214
+2.43%
|
$57,498
$7.01 P/Share
|
|
Dec 29
2020
|
Robert W Duggan |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
376,065
+3.12%
|
$2,632,455
$7.01 P/Share
|
|
Oct 08
2020
|
Mitchell E. Levinson Chief Strategy Officer |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
856
+3.12%
|
$5,992
$7.01 P/Share
|